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ing, thus reducing fibrosis in animal models and some 
 patients with tumor-associated fibrosis. At present, the de-
velopment of antifibrotic therapies takes place in other dis-
eases such as lung and liver fibrosis. This is partially due to a 
lack of experimental models for gut fibrosis and the fact that 
reliable readouts (MRI, serum markers) in patients are lack-
ing. It will be important to test the above-mentioned newly 
available treatment strategies in IBD to profit from progress 
in other fibrotic diseases.  © 2014 S. Karger AG, Basel 
 Introduction 
 Up to two thirds of patients with Crohn’s disease (CD) 
may develop either a stricturing or penetrating disease 
course within 10 years after diagnosis  [1] . Up to 80% of 
all CD patients undergo surgery at least once during the 
course of their disease  [2–4] . In half of these patients, in-
testinal obstructions and strictures are the indication for 
surgery. 
 Recent data by Pittet et al.  [5] from the Swiss IBD Co-
hort group indicate that over a period of 40 years more 
than 75% of patients have to undergo surgery. The most 
frequent reason for surgery right after diagnosis of CD is 
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fibrosis  [5] . Over the next 25 years there is almost a linear 
decrease in the proportion of surgery-free patients as seen 
in  figure 1 . 
 Whereas we are able to control for inflammation better 
and better, an effective preventive therapy for fibrosis or a 
pharmacological approach that even could reduce fibrosis 
is virtually absent. Most gastroenterologists believe that 
surgery can be avoided by preventing or reducing inflam-
mation. This concept has also been brought forward by 
Pariente et al.  [6] . In this concept, surgery occurs upon a 
chronic subclinical inflammation and subsequent fibrosis 
 [6] . The evidence, however, to support this concept is 
weak. To some extent fibrosis might be independent from 
the inflammatory process. We find fibrotic strictures also 
in patients fibrotic strictures also in patients without IBD 
at surgical anastomosis, indicating that fibrosis might oc-
cur completely without any basic inflammation. 
 It is obvious that fibrosis research and development of 
potential therapeutic avenues is much more advanced in 
other fibrotic diseases when compared to IBD. Therefore, 
it is important to think ‘out of the box’ and to learn from 
those areas to improve the situation of patients with CD 
or ulcerative colitis. Whereas there is some progress in 
basic research on fibrosis in IBD, clinical research and fi-
brosis therapy is still virtually absent. An indicator for the 
interest in fibrosis certainly is that the 4th Scientific 
Workshop of the European Crohn’s and Colitis Founda-
tion (ECCO) was focused on the subject of fibrosis in CD. 
A series of review articles have recently been published on 
the subject, featuring pathogenesis, markers and poten-
tial treatment  [7, 8] . 
 Which Therapeutic Targets Have Been Identified in 
Other Fibrotic Diseases? 
 Basic research in liver fibrosis not only focuses on the 
anti-inflammatory agents and the reduction of injury as 
is usually done in CD  [9–12] . Several other fields of inter-
est have been introduced in liver fibrosis research. Inhib-
itors of proliferation and angiogenesis have been shown 
to be successful in prevention of liver fibrosis. An exam-
ple is the Hedgehog signaling pathway. It is a signaling 
pathway identified to transmit information to embryonic 
cells required for proper development. An involvement 
of this factor or pathway has recently been discussed also 
for idiopathic pulmonary fibrosis and other fibrotic dis-
eases  [13, 14] . The Hedgehog pathway was found to be 
activated in lungs of patients with idiopathic pulmonary 
fibrosis, thereby contributing to idiopathic pulmonary fi-
brosis pathogenesis by increasing the proliferation, mi-
gration, extracellular matrix production and survival of 
pulmonary fibroblasts  [13] .
 Fibrogenesis inhibitors also have been tested in animal 
models of fibrotic disease. Among those direct fibrogen-
esis inhibitors are TGF-β1 and TGF-β1 receptor antago-
nists  [15–19] , hepatocyte growth factor agonist  [20] , an-
giotensin-receptor antagonists  [21, 22] , ACE inhibitors 
 [23] , connective tissue growth factor antagonists  [24, 25] , 
cannabinoid receptor 1 antagonist  [26–28] and lysophos-
phatidic acid receptor type 1 antagonists  [29, 30] . In ad-
dition to direct fibrogenesis inhibitors, enhanced degra-
dation of extracellular matrix proteins has proven to be 
promising in a number of experimental models  [31, 32] . 
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 Fig. 1. Proportion of surgery-free patients 
in the Swiss IBD cohort study over time 
(according to  [5] ). 
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Tested substances in those models were tissue inhibitors 
of metalloproteinases  [33] , TGF-β antagonists, cell mod-
ulation therapy and inhibitors of lysyl oxidase-like 2 
(LOXL2)  [34] . The LOX enzyme also plays an important 
role in therapeutic trials in lung fibrosis. Therefore, this 
interesting molecule that is not studied in CD could be 
of future interest. Lysyl oxidase-like (LOX) refers to a 
group of copper-dependent amine oxidases that catalyze 
the covalent cross-link of collagens and elastin in the ex-
tracellular environment  [35] . LOXL2 as a prototypic 
member of the group plays an essential role in the forma-
tion of connective tissue. It thus influences the mechan-
ical properties of the extracellular matrix  [35] . A dys-
regulation of LOXL2 has been discussed to play an im-
portant role in the pathogenesis of fibrosis in different 
organs. 
 Why Is Fibrosis Research in IBD Not More Advanced? 
 Fibrosis research, especially with respect to the devel-
opment of therapeutic targets, is hampered by two major 
problems. While there are some models of intestinal fi-
brosis available, they all have certain disadvantages. Ani-
mal models of fibrosis have been recently summarized 
and reviewed by Pizarro and colleagues  [36, 37] . In most 
of the animal models, fibrosis is either induced by chem-
icals such as dextran sodium sulfate  [38–40] or 2,4,6-
trinitrobenzenesulfonic acid  [41–48] , or by bacterial cell 
wall products such as peptidoglycan  [49, 50] . 
 Only one spontaneous model, the SAMP1/YitFc 
mouse strain, which develops CD-like ileitis, has been 
studied in detail by Pizarro and colleagues  [37, 51] . Cer-
tainly this mouse model has the great advantage that in-
testinal fibrosis indeed develops spontaneously without 
any chemical induction that may not reflect natural 
pathophysiology and that there is additional inflamma-
tion in the terminal ileum similar to what is seen in hu-
mans. On the other hand, the model is not very stable and 
seems to depend to some extent on the bacterial flora  [52] . 
Also, fibrosis in the chemically induced models is variable 
and only occurs after a long time. Therefore, for the study 
of intestinal fibrosis, new models would be highly war-
ranted that develop fibrosis rapidly and reliably to a con-
stant extent. 
 To develop such a model of intestinal fibrosis with the 
advantages mentioned above, we adapted a heterotopic 
tracheal transplant model that was developed a long time 
ago for the investigation of bronchiolitis obliterans (BO) 
after lung transplantation  [53, 54] . BO also occurs after 
allogeneic stem cell transplantation. Single nucleotide 
polymorphisms that are relevant susceptibility factors in 
the pathogenesis of CD such as NOD2 were also shown 
to contribute to the risk of developing BO  [55] . 
 To study therapeutic prevention of BO, a piece of tra-
chea was transplanted heterotopically into the neck fold 
of rats where it developed fibrosis with a constant time 
course  [53, 54] . We adopted this rat model and trans-
planted small parts of the small intestine also in the neck 
fold of isogenic animals  [56] . Donor (Brown Norway or 
Lewis rats) small bowel resections were transplanted sub-
cutaneously into the neck of recipients (Lewis rats)  [56] . 
Grafts were explanted 2, 7, 14 and 21 days after transplan-
tation. The neck fold was chosen because the animals are 
unable to scratch themselves there, avoiding mechanical 
irritation that can influence the development of fibrosis. 
Rapid fibrosis occurred similar to the BO model. Colla-
gen expression was increased with time  [56] . Lumen 
obliteration was associated with increased expression of 
fibrosis-mediators such as α V β 6 integrin, IL-13 and TGF-β 
 [56] . Several typical histologic and molecular features of 
intestinal fibrosis were observed in this heterotopic intes-
tinal graft model. Within 3 weeks there was an almost 
tenfold increase in fibrotic layer thickness. This indicates 
that there is indeed rapid and stable fibrosis development. 
mRNA expression of collagen-1 was increased 100-fold 
after 3 weeks as compared to baseline  [56] . This model 
may to some extend solve the problem of a lack of a rapid 
and reliable model of intestinal fibrosis. It will be possible 
to study and screen a number of agents on their ability to 
prevent intestinal fibrosis, thus identifying promising 
drug candidates for the prevention/treatment of intesti-
nal fibrosis. 
 Why Do We Have No Clinical Trials on the Prevention 
of Intestinal Fibrosis? 
 There is a second aspect that prevents the develop-
ment of successful therapies for CD fibrosis: the lack of a 
reliable endpoint for clinical trials. So far we do not have 
any reliable biomarker that would fulfill the criteria for a 
good endpoint in a respective clinical study. There are no 
reliable serum markers of intestinal fibrosis that would 
nicely correlate with the process of fibrosis or the degree 
of collagen deposition. YKL-40 has been reported to be a 
marker for liver fibrosis  [57] . It is also increased when 
intestinal strictures are present, but the correlation coef-
ficient is only r = 0.457 and serum levels are also in-
creased during active inflammation  [58] making this 
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marker not a good candidate for a surrogate marker in 
clinical trials. 
 All of the other ‘marker-candidates’ studied so far have 
not proven a sufficient correlation with the degree of in-
testinal fibrosis to be useful for monitoring antifibrotic 
therapy. It could be that the volume of the fibrotic area is 
too small in intestinal fibrosis to be represented reliably 
by a serum marker.
 On the other hand, imaging techniques have not been 
developed to a state where they can be used as clinical 
endpoints. In CT scans or MRI as well as ultrasound, the 
evaluation of fibrosis mostly relies on subjective parame-
ters. Contrast enhancement is usually seen as a sign of 
inflammation. However, active fibrosis could also lead to 
contrast enhancement because it is a biologically and 
metabolically highly active process. Only when fibrosis is 
already established and a full scar or sclerosis has devel-
oped is contrast enhancement no longer seen. A recently 
developed technique developed for the detection of intes-
tinal fibrosis in MRI is ‘magnetization transfer’  [49, 50] . 
MR magnetization transfer imaging has several advan-
tages as compared to conventional MRI. Magnetization 
transfer generates contrast that is primarily determined 
by the fraction of large macromolecules or immobilized 
phospholipid cell membranes in tissue  [50] . This means 
that bone, cartilage and muscle will also show a high sig-
nal in magnetization transfer. Nevertheless, it is possible 
to identify fibrotic strictures in the gut. In a recent study 
in normal nonfibrotic bowel wall segments, an interme-
diate magnetization transfer ratio of 25.4 ± 3.4% was 
measured  [59] . In contrast, the magnetization transfer ra-
tio was significantly increased in bowel wall segments 
with fibrotic areas (35.3 ± 4.0%, p < 0.0001)  [59] . In bow-
el segments with acute inflammation and no fibrosis, the 
mean magnetization transfer ratio was slightly lower than 
in the normal bowel wall without reaching a level of sig-
nificance (22.9 ± 2.2%). As is obvious from the above 
numbers, it is possible to quantify magnetization transfer 
and give a ratio to have a quantification of tissue fibrosis. 
If magnetization transfer in MRI is further developed, 
this may be a promising technique to quantify intestinal 
fibrosis and to provide a quantitative endpoint for clinical 
trials on intestinal fibrosis. Currently, a large trial has 
been initiated in Europe that will investigate the useful-
ness of magnetization transfer as an endpoint for clinical 
trials of intestinal fibrosis. On the other hand, new ultra-
sound techniques and FibroScan ® may be promising 
 [60–64] . New developments have taken place that could 
allow quantification of fibrosis with ultrasound in the 
near future. 
 Which Endpoints Are Used in Clinical Trials on 
Fibrosis in Clinical Trials on Fibrosis in Other 
Diseases? 
 As mentioned earlier, the lack of a clinical endpoint is 
a major disadvantage for trials on intestinal fibrosis. So, 
why are there reliable endpoints in other diseases and 
what are those endpoints? FibroScan is used for liver fi-
brosis, but the method so far is not perfectly reproducible 
 [65] . On the other hand, liver biopsy is frequently seen as 
the gold standard, but has the disadvantage of a patchy 
distribution of fibrosis in many patients. Results might be 
hampered by this fact and therefore patient numbers in-
cluded in those studies must be rather high to avoid a bias 
by the patchiness of the tissue sample. 
 In contrast, there is a very reliable endpoint for clinical 
trials in idiopathic pulmonary fibrosis. This is the reason 
why most clinical fibrosis trials are done in this indica-
tion. The endpoint in all those trials is the ‘forced vital 
capacity’  [66] . The vital capacity is the maximum amount 
of air a person can expel from the lungs after maximum 
inhalation. A patient’s vital capacity of course can easily 
be measured by a spirometer in a regular setting. This 
endpoint for clinical trials can be measured without any 
invasive methods, can be easily repeated, and is not of any 
disadvantage or risk for the patient  [66] . Therefore, idio-
pathic pulmonary fibrosis is the main indication of the 
development of antifibrotic drugs for many pharmaceuti-
cal companies despite the fact that the number of patients 
with idiopathic pulmonary fibrosis is much lower as com-
pared to patients with intestinal fibrosis due to CD. 
 The factors that have been identified to play a role in 
the pathogenesis of idiopathic pulmonary fibrosis are 
similar to those identified to be relevant during intestinal 
fibrosis. Data show that growth factors such as platelet-
derived growth factor (PDGF), epidermal growth factor, 
TGF-α and -β, or endothelin-1 play an important role in 
promoting intestinal fibrosis and deposition of collagen 
 [67–70] . Prostaglandin E 2 seems to inhibit pulmonary fi-
brosis  [71, 72] . IL-4, IL-13, fibroblast growth factor, insu-
lin-like growth factor and cytokines such as IL-1 are also 
profibrogenic  [73–75] . In principal all of those mediators 
also play a role in intestinal fibrosis, indicating that a fi-
brotic stimulus is probably locally active and that the 
mechanisms are very similar in lung and intestinal fibro-
sis. This indicates that results derived from animal studies 
and clinical trials in idiopathic pulmonary fibrosis may be 
transferable to intestinal fibrosis, which calls for more sci-
entific interaction between pulmonologists and gastroen-
terologists.
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 Clinical Trials in Idiopathic Pulmonary Fibrosis 
 Despite the prototypic role of idiopathic lung fibrosis 
for fibrotic disease and the above-mentioned clear clini-
cal endpoint, so far only one substance is approved for the 
treatment of idiopathic pulmonary fibrosis and one has 
an orphan drug status. 
 The only currently approved drug for lung fibrosis is 
pirfenidone  [76–79] . It is an orally active, small molecule 
that inhibits the synthesis of profibrotic and inflamma-
tory mediators. Chemically, pirfenidone is 5-methyl-
1-phenylpyridin-2-one  [80] . The precise mechanism of 
action of pirfenidone is still unknown. Pirfenidone has 
several effects that can be interpreted as being ‘antifibrot-
ic’. Among others, it reduces the expression of collagen 
in fibroblast and muscle cells in vitro  [80] . In 2 out of 3 
phase 3 trials, pirfenidone significantly reduced the de-
cline of the forced vital capacity in patients with idio-
pathic pulmonary fibrosis  [76, 81] . This finally led to ap-
proval by the FDA. Recently another phase 3 trial on pir-
fenidone was published in  The New England Journal of 
Medicine  [77] (in the same issue where the study on nin-
tedanib was published). This phase 3 trial studied 555 
patients with idiopathic pulmonary fibrosis who were as-
signed to receive either oral pirfenidone (2,403 mg/day) 
or placebo over a period of 52 weeks  [77] . The primary 
endpoint of this trial was again the change in forced vital 
capacity or death at week 52. In the pirfenidone group, a 
relative reduction of 47.9% in the proportion of patients 
who had an absolute decline of 10% or more in the per-
centage of the predicted forced vital capacity or who died 
was observed  [77] . Thus, the whole trial achieved signif-
icance and confirmed that pirfenidone successfully pre-
vents progress of idiopathic pulmonary fibrosis  [77] . Un-
fortunately, gastrointestinal and skin-related adverse 
events were more common in the pirfenidone group 
 Table 1.  Clinical trials in idiopathic pulmonary fibrosis
Trial No. Title Target Sponsor
NCT01335464, 
NCT01335477
Efficacy and Safety of Nintedanib (BIBF 
1120) in Idiopathic Pulmonary Fibrosis; 
two replicate 52-week, randomized, 
double-blind trials (INPULSIS-1 and 
INPULSIS-2) in 1,066 patients
Phase 3: intracellular tyrosine kinase 
inhibitor 
Boehringer 
Ingelheim
NCT00786201 A Study to Evaluate the Safety and 
Effectiveness of CNTO 888 Administered 
Intravenously (IV) in Participants With 
Idiopathic Pulmonary Fibrosis (IPF)
Phase 2: this study tests the safety and 
effectiveness of CNTO 888 compared to 
placebo; CNTO 888 (carlumab) is a 
human monoclonal antibody against 
CC-chemokine ligand 2 (CCL2)
Centocor Inc.
NCT01872689 A Study of Lebrikizumab in Patients With 
Idiopathic Pulmonary Fibrosis
Phase 2: lebrikizumab is an anti-IL-13 
antibody
Hoffmann-
La Roche 
NCT01366209 Efficacy and Safety of Pirfenidone in 
Patients With Idiopathic Pulmonary 
Fibrosis (IPF) 
PIPF-016 (ASCEND) is a randomized, 
double-blind, placebo-controlled, phase 3 
study
InterMune 
NCT00262405 Zileuton for the Treatment of Idiopathic 
Pulmonary Fibrosis
5-Lipoxygenase inhibitor University of 
Michigan 
NCT01362231,
NCT01769196
A Study to Evaluate the Safety and 
Efficacy of GS-6624 (Formerly AB0024) in 
Patients With Idiopathic Pulmonary 
Fibrosis
Phase 1 study completed, phase 2 study 
active: simtuzumab (GS-6624; formerly 
AB0024) targets LOXL2, which is an 
enzyme that promotes cross-linking of 
type 1 collagen in all types of fibrosis
Gilead Sciences
NCT01629667 A Phase 2, Randomized Dose-ranging 
Study to Evaluate the Efficacy of 
Tralokinumab in Adults With Idiopathic 
Pulmonary Fibrosis
Tralokinumab is a human recombinant 
monoclonal antibody that specifically 
binds human IL-13
MedImmune LLC
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than in the placebo group. Pain and diarrhea were among 
the gastrointestinal side effects. This might limit the ac-
ceptability of pirfenidone for the treatment of CD pa-
tients  [77] . 
 In May 2014 an also large trial on the efficacy and safe-
ty of nintedanib (BIBF1120) in idiopathic pulmonary fi-
brosis was published in  The New England Journal of Med-
icine  [82] ( table 1 ). Nintedanib is an intracellular tyrosine 
kinase inhibitor. INPULSIS-1 and INPULSIS-2 were two 
replicate 22-week, randomized, double-blind, phase 3 tri-
als in altogether 1,066 patients  [82] . The primary end-
point was (not surprisingly) the reduction in the annual 
rate of decline in forced vital capacity. Both trials reached 
their endpoints with high significance. In INPULSIS-1 
the annual rate of changed enforced vital capacity was 
–114.7 ml with nintedanib versus –239.9 ml in the pla-
cebo group (Δ125.3 ml, p < 0.001)  [82] . In INPULSIS-2 
the patients treated with nintedanib lost 113.6 ml of their 
forced vital capacity over the 12-month trial period, 
whereas the placebo-treated patients lost 207.3 ml of their 
forced vital capacity (Δ93.7 ml, p < 0.001)  [82] . It is strik-
ing that in those two studies the effect of the drug was so 
similar. Obviously, this tyrosine kinase inhibitor effec-
tively reduces the progress of pulmonary fibrosis. How-
ever, application in intestinal fibrosis may be hampered 
by the most important side effect reported in those two 
trials: the most frequent adverse event in the nintedanib 
groups was diarrhea which occurred in 61.5% of the pa-
tients in INPULSIS-1 and in 63.2% in INPULSIS-2  [82] . 
It caused therapy to be discontinued in a significant num-
ber of patients. As is obvious, CD patients would be even 
more affected by an induction of diarrhea by the study 
drug. 
 However, it might be possible to use lower dosages of 
nintedanib in patients with CD fibrosis. The dosage for 
idiopathic pulmonary fibrosis has been determined in 
earlier studies such as the TOMORROW trial  [83, 84] .
In the TOMORROW trial, dosages of nintedanib 
(BIBF1120) less than 150 mg twice daily, however, were 
not effective  [84] . 50 mg once daily, 50 mg twice daily or 
100 mg twice daily were not significantly different to pla-
cebo with respect to the annual rate of change in forced 
vital capacity as published by Woodcock et al.  [84] . 
 With respect to the pathophysiological targets, ninte-
danib could also work in intestinal fibrosis. It dose-de-
pendently inhibits the phosphorylation of several recep-
tors of growth factors such as the phosphorylation of 
PDGF receptor by PDGF-BB as shown by Wollin et al. 
 [85] . As PDGF also plays a role in intestinal fibrosis, this 
pathway could well be effective. 
 A number of different antibodies and compounds 
are being tested at present for the indication of idio-
pathic pulmonary fibrosis ( table 1 ): Centocore is per-
forming a phase 2 trial on the safety and effectiveness of 
CNTO 888 compared to placebo (NCT00786201). 
CNTO 888 is also named carlumab and is a human 
monoclonal antibody against the chemokine (C-C mo-
tif) ligand 2, which has earlier been referred to as mono-
cyte chemotactic protein 1, which is known to recruit 
monocytes, activated and memory T cells, and dendrit-
ic cells to the sites of inflammation  [86–88] . A role for 
monocyte chemotactic protein 1 has already been shown 
in intestinal inflammation and fibroblast activation 
 [89–91] . 
 Another phase 2 trial studied the effect of lebriki - 
zumab in patients with idiopathic pulmonary fibrosis 
(NCT01872689). Lebrikizumab is an anti-IL-13 antibody 
manufactured by Hoffmann-La Roche. IL-13 also has 
been associated with intestinal fibrosis and is generally 
believed to be a profibrotic cytokine  [92–95] . 
 Another interesting drug that is being studied in the 
area of idiopathic pulmonary fibrosis is simtuzumab 
 (GS-6624; formerly AB0024). A phase 1 study was 
 completed and a phase 2 study is active (NCT01362231; 
NCT01769196). This antibody targets the above-men-
tioned LOXL2. The trials are being performed by Gilead 
Sciences, and the phase 1 and 2 trials seem to be promis-
ing. 
 MedImmune is conducting a phase 2 trial in idiopath-
ic pulmonary fibrosis which is a randomized, dose-ranged 
study to evaluate the efficacy of tralokinumab in adults. 
Tralokinumab is a human recombinant monoclonal an-
tibody that specifically binds human IL-13. 
 A list of published clinical trials in pulmonary fibrosis 
can be seen in  table 2  [96] . It shows that endothelin recep-
tor antagonists have been studied with some success and 
that at the moment tyrosine kinase inhibitors and pirfeni-
done have demonstrated the most promising results  [96] . 
On the other hand, IFN-γ has been studied in investiga-
tor-initiated trials  [97, 98] . It is an attractive therapeutic 
candidate as it regulates both macrophages and fibroblast 
functions. IFN-γ inhibits fibrogenic growth factors 
(FGFs), namely FGF2 and basic FGF, and a variety of 
neutrophil-derived cytokines. 
 Other substances also have shown some effects in 
models of pulmonary fibrosis. Suramin is a sulfonated 
naphthyl-urea that antagonizes the effects of certain 
growth factors including TGF-β, insulin-like growth fac-
tor-1, PDGF and FGF. On the other hand – as most 
TGF-β antagonists – it delays wound healing which could 
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be deleterious in CD. Relaxin is another factor studied in 
the field of lung fibrosis. Relaxin inhibits TGF-β-induced 
collagen and fibronectin synthesis by fibroblasts, and in-
creases the expression of matrix metalloproteinase 1, 
which is able to degrade collagen. 
 Clinical Trials in Other Fibrotic Diseases 
 A number of clinical trials also have been finished or 
are currently ongoing in liver fibrosis ( table  3 ). Simtu-
zumab (GS-6624; formerly AB0024), the antibody that 
Trial Drug Mechanism of action Reference
IFIGENIA N-acetylcysteine antioxidant  99
PANTHER-IPF prednisone
azathioprine
N-acetylcysteine
antioxidant
immunosuppression
100
Taniguchi pirfenidone antifibrotic 101
CAPACITY 1
CAPACITY 2
pirfenidone antifibrotic 102
ACE-IPF warfarin anticoagulant 103
TOMORROW BIBF1120 tyrosine kinase inhibitor 104
Daniels imatinib mesylate tyrosine kinase inhibitor 105
STEP-IPF sildenafil phosphodiesterase-5 inhibitor 106
BUILD-1 bosentan endothelin receptor antagonist 107
BUILD-2 bosentan endothelin receptor antagonist 108
ARTEMIS-IPF ambrisentan endothelin receptor antagonist 109
MUSIC-IPF macitentan endothelin receptor antagonist 110
Raghu IFN-γ immunomodulation  97
INSPIRE IFN-γ immunomodulation  98
Table 2. Completed trials in idiopathic 
pulmonary fibrosis (modified according 
to [96])
 Table 3. Clinical trials in liver fibrosis
Trial No. Title Target Sponsor
NCT01672866 Simtuzumab (GS-6624) in the Treatment of 
Liver Fibrosis in Subjects With Advanced 
Liver Fibrosis But Not Cirrhosis Secondary 
to Non-Alcoholic Steatohepatitis (NASH)
simtuzumab (GS-6624; formerly AB0024)
targets LOXL2, which is an enzyme that 
promotes cross-linking of type 1 collagen in 
all types of fibrosis
Gilead Sciences
NCT01707472 A Phase 2a Study of Simtuzumab in HIV 
and/or Hepatitis C-Infected Subjects With 
Liver Fibrosis
phase 2a: simtuzumab (GS-6624; formerly 
AB0024) targets LOXL2, which is an enzyme 
that promotes cross-linking of type 1 
collagen in all types of fibrosis
Gilead Sciences
NCT01217632 A Study of FG-3019 in Subjects With Liver 
Fibrosis Due to Chronic Hepatitis B 
Infection
human monoclonal antibody against 
connective tissue growth factor; has been 
granted orphan drug designation by the 
FDA for the treatment of idiopathic 
pulmonary fibrosis
FibroGen 
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targets LOXL2, is also being studied in liver fibrosis in 
subjects with advanced liver fibrosis, but not cirrhosis 
secondary to NASH. Two phase 2 trials are registered. 
The results have not been published yet.
 FibroGen is studying FG-3019 in subjects with liver 
fibrosis due to chronic hepatitis B infection. FG-3019 is a 
human monoclonal antibody against connective tissue 
growth factor. The drug has been granted orphan drug 
designation by the FDA for the treatment of idiopathic 
pulmonary fibrosis due to promising data from a clinical 
trial there. 
 Conclusion 
 As is obvious from the clinical trials mentioned above, 
antifibrotic treatments are mainly studied in idiopathic 
pulmonary fibrosis and to a lesser extent in hepatic fibro-
sis, whereas there are almost no trials ongoing in intesti-
nal fibrosis. This is mainly due to two factors. First, we do 
not have animal models of intestinal fibrosis that are reli-
able and develop fibrosis fast enough to do a number of 
screening experiments. Even more importantly, intesti-
nal fibrosis is hard to assess and there are no reliable end-
points for clinical trials. Magnetization transfer and new 
ultrasound techniques may provide us with these end-
points; however, they need financial support to be further 
developed in the near future. At present a new European-
wide clinical trial has been started to validate MRI for the 
assessment of intestinal fibrosis. 
 We should also join in efforts to develop new animal 
models for intestinal fibrosis. Therapies successful in pul-
monary fibrosis should now be studied in intestinal fibro-
sis. The models available so far may be a starting point.
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